BACKGROUND: The drug of choice for leishmaniasis is pentavalent antimony and different regimens are under continuous evaluation. The ideal therapy should be simple, effective, and with no or minor side-effects. In this paper we have studied the efficacy of intralesionally applied antimony in New World cutaneous leishmaniasis. METHODS: Seventy-four patients from Rio de Janeiro state, Brazil, and presenting with single ulcerative cutaneous lesions mainly located on the trunk or extremities were enrolled in the study. The drug employed was N-methyl glucamine (425 mg of Sbv in each 5 ml ampoule). Each lesion was infiltrated with the drug at the four cardinal points in order to achieve complete blanching. RESULTS: Of the 74 patients, 59 (80%) were healed after a 12-week interval. Extensive follow-up (up to 10 years) disclosed no relapses or the development of mucosal lesions. CONCLUSIONS: The aim of therapy in New World cutaneous leishmaniasis is the healing of the cutaneous lesion and the prevention of late mucosal damage. Both conditions were achieved with the treatment employed with no side-effects and a considerable decrease in costs. In addition, the method is easy to apply in the field.
BACKGROUND: The drug of choice for leishmaniasis is pentavalent antimony and different regimens are under continuous evaluation. The ideal therapy should be simple, effective, and with no or minor side-effects. In this paper we have studied the efficacy of intralesionally applied antimony in New World cutaneous leishmaniasis. METHODS: Seventy-four patients from Rio de Janeiro state, Brazil, and presenting with single ulcerative cutaneous lesions mainly located on the trunk or extremities were enrolled in the study. The drug employed was N-methyl glucamine (425 mg of Sbv in each 5 ml ampoule). Each lesion was infiltrated with the drug at the four cardinal points in order to achieve complete blanching. RESULTS: Of the 74 patients, 59 (80%) were healed after a 12-week interval. Extensive follow-up (up to 10 years) disclosed no relapses or the development of mucosal lesions. CONCLUSIONS: The aim of therapy in New World cutaneous leishmaniasis is the healing of the cutaneous lesion and the prevention of late mucosal damage. Both conditions were achieved with the treatment employed with no side-effects and a considerable decrease in costs. In addition, the method is easy to apply in the field.
Authors: Jaime Soto; David Paz; Daniela Rivero; Paula Soto; Jorge Quispe; Julia Toledo; Jonathan Berman Journal: Am J Trop Med Hyg Date: 2016-02-22 Impact factor: 2.345
Authors: Yavuz Yesilova; Hacer Altın Surucu; Nurittin Ardic; Mustafa Aksoy; Abdullah Yesilova; Steve Oghumu; Abhay R Satoskar Journal: J Dermatolog Treat Date: 2015-06-24 Impact factor: 3.359
Authors: Manuel Calvopiña; William Cevallos; Yolanda Paredes; Edison Puebla; Jessica Flores; Richard Loor; José Padilla Journal: Am J Trop Med Hyg Date: 2017-10-10 Impact factor: 2.345
Authors: Erica de Camargo Ferreira e Vasconcellos; Maria Inês Fernandes Pimentel; Cláudia Maria Valete-Rosalino; Maria de Fátima Madeira; Armando de Oliveira Schubach Journal: Rev Inst Med Trop Sao Paulo Date: 2014 Jul-Aug Impact factor: 1.846
Authors: Madelon Novato Ribeiro; Maria Inês Fernandes Pimentel; Armando de Oliveira Schubach; Raquel de Vasconcellos Carvalhães de Oliveira; José Liporage Teixeira; Madson Pedro da Silva Leite; Monique Fonseca; Ginelza Peres Lima dos Santos; Mariza Matos Salgueiro; Erica de Camargo Ferreira e Vasconcellos; Marcelo Rosandiski Lyra; Mauricio Naoto Saheki; Claudia Maria Valete-Rosalino Journal: Rev Inst Med Trop Sao Paulo Date: 2014 Jul-Aug Impact factor: 1.846